Literature DB >> 2667937

Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases.

S M Grant1, H D Langtry, R N Brogden.   

Abstract

Ranitidine, a histamine H2-receptor antagonist, is now well established as a potent inhibitor of gastric acid secretion effective in the treatment and prophylaxis of gastrointestinal lesions aggravated by gastric acid secretion. Therapeutic trials involving several thousands of patients with peptic ulcer disease confirm that ranitidine 300mg daily administered orally in single or divided doses is at least as effective as cimetidine 800 to 1000mg daily in increasing the rate of healing of duodenal and gastric ulcers. Similar dosages of ranitidine have been shown to relieve the symptoms of reflux oesophagitis and heal or prevent gastrointestinal damage caused by ulcerogenic drugs. Ranitidine 150mg orally at night maintains ulcer healing in the long term. Ranitidine has also demonstrated good results in the treatment of Zollinger-Ellison syndrome and in the prevention of aspiration pneumonitis when given prior to surgery and to pregnant women at full term. It may also have a place in the management of acute upper gastrointestinal bleeding and in the prevention of stress ulcers in the intensive care setting, although these areas require further investigation. Ranitidine has been used safely in obstetric patients during labour, in children, the elderly, and in patients with renal impairment when given in appropriate dosages. The drug is very well tolerated and is only infrequently associated with serious adverse reactions or clinically significant drug interactions. Even at high dosages, ranitidine appears devoid of antiandrogenic effects. Ranitidine is clearly comparable or superior to most other antiulcer agents in the treatment and prevention of a variety of gastrointestinal disorders associated with gastric acid secretion. With its favourable efficacy and tolerability profiles, ranitidine must be considered a first-line agent when suppression of gastric acid secretion is indicated.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2667937     DOI: 10.2165/00003495-198937060-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  375 in total

1.  Immune-mediated thrombocytopenia associated with ranitidine therapy.

Authors:  P R Gibson; M E Pidcock
Journal:  Med J Aust       Date:  1986 Dec 1-15       Impact factor: 7.738

2.  Influence of cimetidine and ranitidine on ethanol pharmacokinetics.

Authors:  L K Webster; D B Jones; R A Smallwood
Journal:  Aust N Z J Med       Date:  1985-06

3.  Gastric mucus secretion in ranitidine-treated patients.

Authors:  M Guslandi; E Ballarin; A Tittobello
Journal:  Br Med J (Clin Res Ed)       Date:  1981-09-12

4.  A comparative trial of ranitidine 300 mg at night with ranitidine 150 mg twice daily in the treatment of duodenal and gastric ulcer.

Authors:  A Farley; D Lévesque; P Paré; A B Thomson; R Sherbaniuk; A Archambault; K Mahoney
Journal:  Am J Gastroenterol       Date:  1985-09       Impact factor: 10.864

5.  Prevention of duodenal ulcer relapse with ranitidine.

Authors:  R C Mekel; D J den Boer
Journal:  S Afr Med J       Date:  1985-09-14

6.  Single blind comparative study of ranitidine and cimetidine in patients with gastric ulcer. The Belgian Peptic Ulcer Study Group.

Authors: 
Journal:  Gut       Date:  1984-09       Impact factor: 23.059

7.  Day and night aspirin-induced gastric mucosal damage and protection by ranitidine in man.

Authors:  J G Moore; R H Goo
Journal:  Chronobiol Int       Date:  1987       Impact factor: 2.877

8.  Treatment of 'cimetidine-resistant' chronic duodenal ulcers with ranitidine or cimetidine: a randomised multicentre study.

Authors:  M Quatrini; G Basilisco; P A Bianchi
Journal:  Gut       Date:  1984-10       Impact factor: 23.059

9.  Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine.

Authors:  R S Ehsanullah; M C Page; G Tildesley; J R Wood
Journal:  BMJ       Date:  1988-10-22

10.  Comparison of ranitidine, domperidone maleate and ranitidine + domperidone maleate in the short-term treatment of reflux oesophagitis.

Authors:  E Masci; P A Testoni; S Passaretti; M Guslandi; A Tittobello
Journal:  Drugs Exp Clin Res       Date:  1985
View more
  39 in total

1.  Pharmacokinetic-interaction study of didanosine and ranitidine in patients seropositive for human immunodeficiency virus.

Authors:  C A Knupp; F M Graziano; R M Dixon; R H Barbhaiya
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

2.  pH-feedback controlled infusions of ranitidine are no more effective than fixed-dose infusions in reducing gastric acidity and variability in antisecretory responses.

Authors:  C H Wilder-Smith; F Halter; W Häcki; H S Merki
Journal:  Br J Clin Pharmacol       Date:  1992-05       Impact factor: 4.335

3.  Bioavailability prediction based on molecular structure for a diverse series of drugs.

Authors:  Joseph V Turner; Desmond J Maddalena; Snezana Agatonovic-Kustrin
Journal:  Pharm Res       Date:  2004-01       Impact factor: 4.200

4.  Gastroretentive drug delivery system of ranitidine hydrochloride: formulation and in vitro evaluation.

Authors:  Brijesh S Dave; Avani F Amin; Madhabhai M Patel
Journal:  AAPS PharmSciTech       Date:  2004-04-08       Impact factor: 3.246

5.  Influence of the H2-receptor antagonists cimetidine and ranitidine on the pharmacokinetics of nimodipine in healthy volunteers.

Authors:  W Mück; W Wingender; M Seiberling; E Woelke; K D Rämsch; J Kuhlmann
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

6.  Pharmacokinetics and bioequivalence of ranitidine and bismuth derived from two compound preparations.

Authors:  Quan Zhou; Zou-Rong Ruan; Hong Yuan; Bo Jiang; Dong-Hang Xu
Journal:  World J Gastroenterol       Date:  2006-05-07       Impact factor: 5.742

7.  Design and evaluation of a novel matrix type multiple units as biphasic gastroretentive drug delivery systems.

Authors:  Meka Lingam; Thadisetty Ashok; Vobalaboina Venkateswarlu; Yamsani Madhusudan Rao
Journal:  AAPS PharmSciTech       Date:  2008-12-31       Impact factor: 3.246

8.  Floating osmotic drug delivery system of ranitidine hydrochloride: development and evaluation--a technical note.

Authors:  Pramod Kumar; Sanjay Singh; Brahmeshwar Mishra
Journal:  AAPS PharmSciTech       Date:  2008-03-18       Impact factor: 3.246

9.  JB-9322, a new selective histamine H2-receptor antagonist with potent gastric mucosal protective properties.

Authors:  B Palacios; M J Montero; M A Sevilla; L S Román
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

10.  Biodegradability and ecotoxicitiy of tramadol, ranitidine, and their photoderivatives in the aquatic environment.

Authors:  Marlies Bergheim; Reto Gieré; Klaus Kümmerer
Journal:  Environ Sci Pollut Res Int       Date:  2011-06-17       Impact factor: 4.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.